Close

BIO Says Maine Price Control Law Will Hurt Patients, Stifle Biotech Innovation

WASHINGTON, D.C. (May 12, 2000) Carl B. Feldbaum,president of the Biotechnology Industry Organization (BIO), issued the following statement concerning a Maine law that ultimately will result in...

BIO Supportive of FDA Announcement on Biotech Policies

(Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), issued the following statement today regarding FDA Commissioner Jane Henney’s announcement regarding the agency’s...

XENOTRANSPLANTATION: The Benefits and Risks of Special Organ Transplantation

A Position Paper fromThe Biotechnology Industry Organization

Executive Summary

1. Human organ transplantation faces a significant challenge because the need for this procedure far exceeds the...

Testimony on the Proposed Rule on Confidentiality of Patient Records

Regarding the Proposed Rule on Confidentiality of Patient Records Could Impede Research before the Senate Health, Education, Labor and Pensions Committee.

BIO Testifies Proposed Rule On Confidentiality Of Patient Records Could Impede Research

WASHINGTON, D.C. (April 26, 2000) Dr. Joanna C. Horobin, testifying on behalf of the Biotechnology Industry Organization (BIO), said today the Clinton administration’s proposed rule for...

Gorton Bill Will Result In Price Controls, Hurting Seniors, Not Helping Them

WASHINGTON, D.C. (April 26, 2000) Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), issued the following statement in response to U.S. Sen. Slade Gorton’s (R-Wash.)...

BIO Leads Coalition In Support Of Full Funding Of U.S. Patent Office

WASHINGTON, D.C. (April 14, 2000) The BiotechnologyIndustry Organization (BIO) has put together a coalition of entrepreneurial associations to support full funding of the U.S. Patent and Trademark...

BIO Statement Regarding Congressional Report on the Safety of Agricultural Biotechnology

WASHINGTON (APRIL 13, 2000)-- We commend the work of the House subcommittee report which encompasses the research and testimony of distinguished scientists who appeared before Congress during three...

BIO Encouraged By House GOP Drug Benefit Plan

WASHINGTON, D.C., (April 12, 2000) Nancy Bradish Myers, health-care policy and reimbursement counsel for the Biotechnology Industry Organization (BIO), issued the following statement concerning...

BIO Statement Regarding National Research Council Press Release on Genetically Modified Plants

(Dr. Val Giddings, vice president for food and agriculture of the Biotechnology Industry Organization (BIO) today made the following comments in response to the National Research Council (NRC)...